Kadcyla (trastuzumab emtansine) vs Trodelvy (sacituzumab govitecan-hziy)
Kadcyla (trastuzumab emtansine) vs Trodelvy (sacituzumab govitecan-hziy)
Kadcyla (trastuzumab emtansine) is a targeted therapy specifically designed for HER2-positive breast cancer, combining the HER2-targeting properties of trastuzumab with the chemotherapy agent emtansine. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an antibody-drug conjugate that targets the Trop-2 antigen and is used for the treatment of triple-negative breast cancer, a different subtype of breast cancer that does not express HER2, estrogen, or progesterone receptors. The choice between Kadcyla and Trodelvy would largely depend on the specific breast cancer subtype and biomarker status of the individual, as well as the overall treatment plan determined by the healthcare provider.
Difference between Kadcyla and Trodelvy
Metric | Kadcyla (trastuzumab emtansine) | Trodelvy (sacituzumab govitecan-hziy) |
---|---|---|
Generic name | Trastuzumab emtansine | Sacituzumab govitecan-hziy |
Indications | HER2-positive breast cancer | Triple-negative breast cancer, urothelial cancer |
Mechanism of action | HER2 targeting antibody-drug conjugate | Antibody-drug conjugate targeting TROP-2 |
Brand names | Kadcyla | Trodelvy |
Administrative route | Intravenous injection | Intravenous injection |
Side effects | Fatigue, nausea, musculoskeletal pain, hemorrhage, hepatotoxicity | Neutropenia, diarrhea, nausea, fatigue, anemia, vomiting |
Contraindications | Known hypersensitivity to trastuzumab emtansine or any of its excipients | Known hypersensitivity to sacituzumab govitecan-hziy or any of its components |
Drug class | Antibody-drug conjugate | Antibody-drug conjugate |
Manufacturer | Genentech (Roche) | Gilead Sciences, Inc. |
Efficacy
Kadcyla (Trastuzumab Emtansine) for Breast Cancer
Kadcyla (trastuzumab emtansine) is a targeted therapy drug used in the treatment of HER2-positive breast cancer. HER2 is a protein that can promote the growth of cancer cells. In some cancers, notably breast cancer, HER2 is overexpressed, leading to cancer growth. Kadcyla is a combination of trastuzumab, a monoclonal antibody that targets the HER2 protein, and a chemotherapy drug called DM1 (emtansine), which is attached to the antibody. This allows for the direct delivery of the chemotherapy to the cancer cells, sparing normal cells and potentially reducing some chemotherapy side effects.
The efficacy of Kadcyla has been demonstrated in several clinical trials. One pivotal trial that led to its approval was the EMILIA study, which showed that patients with HER2-positive metastatic breast cancer who were treated with Kadcyla had a significant improvement in median progression-free survival compared to those who received lapatinib plus capecitabine, another standard treatment. Furthermore, Kadcyla also showed an increase in overall survival in this patient population. These results have confirmed the role of Kadcyla as an important treatment option for patients with advanced HER2-positive breast cancer.
Trodelvy (Sacituzumab Govitecan-hziy) for Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is another innovative treatment option for patients with breast cancer, specifically for those with triple-negative breast cancer (TNBC), which is a type of cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR), or HER2. Trodelvy is an antibody-drug conjugate which combines a monoclonal antibody that targets the Trop-2 antigen, a protein frequently overexpressed in many epithelial cancers, including TNBC, with a potent chemotherapy drug, SN-38.
The approval of Trodelvy was based on the results of clinical trials that showed a significant benefit in patients with metastatic TNBC who had received at least two prior therapies for metastatic disease. In a phase III trial, Trodelvy significantly improved progression-free survival and overall survival compared to standard single-agent chemotherapy. This marked an important advance in the treatment of TNBC, an aggressive form of breast cancer that previously had limited effective treatment options. Trodelvy's ability to target and deliver chemotherapy directly to cancer cells offers a new hope for patients with this challenging diagnosis.
Regulatory Agency Approvals
Kadcyla
Trodelvy
Access Kadcyla or Trodelvy today
If Kadcyla or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us